

**SUPPLEMENTARY
EUROPEAN SEARCH REPORT**

Application Number
EP 15 82 9426

DOCUMENTS CONSIDERED TO BE RELEVANT				
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)	
X	EP 0 978 287 A1 (MITSUI CHEMICALS INC [JP]) 9 February 2000 (2000-02-09) * abstract, paragraphs [0004] and [0005], [0012]-[0028] and claims * -----	1-9, 12-15	INV. C07K16/28 A61K39/00	
X	WO 2011/073180 A1 (ABLYNX NV [BE]; VERDONCK FRANK [BE]; CORNELIS SIGRID [BE]; STAELLENS ST) 23 June 2011 (2011-06-23) * abstract, p. 2 line 15 - p. 9 line 18, p. 24 line 12 - p. 35 line 29, examples 1-6 and claims *	1-9, 12-15		
X	US 8 551 477 B1 (CROFT MICHAEL [US] ET AL) 8 October 2013 (2013-10-08) * abstract, column 1 line 28 - column 6 line 9, examples 1-10 and claims *	1-9, 12-15		
X	WO 2007/133290 A2 (GENENTECH INC [US]; MARTIN FLAVIUS [US]) 22 November 2007 (2007-11-22) * abstract, p. 2 line 7 - p. 13 line 38, examples 1-8 and claims *	1-9, 12-15	TECHNICAL FIELDS SEARCHED (IPC)	
	-----		A61K C07K	
The supplementary search report has been based on the last set of claims valid and available at the start of the search.			1 Place of search Munich Date of completion of the search 29 November 2017 Examiner Hermann, Patrice	
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document				
T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document				

CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing claims for which payment was due.

Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for those claims for which no payment was due and for those claims for which claims fees have been paid, namely claim(s):

No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for those claims for which no payment was due.

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

see sheet B

All further search fees have been paid within the fixed time limit. The present (supplementary) European search report has been drawn up for all claims.

As all searchable claims could be searched without effort justifying an additional fee, the Search Division did not invite payment of any additional fee.

Only part of the further search fees have been paid within the fixed time limit. The present (supplementary) European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:

None of the further search fees have been paid within the fixed time limit. The present (supplementary) European search report has been drawn up for those parts of the European patent application which relate to the first mentioned in the claims, namely claims:

1-6, 9(completely); 7, 8, 12-15(partially)

LACK OF UNITY OF INVENTION
SHEET B

Application Number

EP 15 82 9426

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

1. claims: 1-6, 9(completely); 7, 8, 12-15(partially)

Invention 1 relates to a OX40L inhibitor in general for use in preventing or treating an autoimmune disease, more particularly wherein said OX40L inhibitor is an anti-CD252 monoclonal antibody comprising the heavy chain CDRs 1-3 amino acid sequences consisting of sequences given in SEQ ID NOS: 5, 6, and 7 respectively and the light-chain CDRs 1-3 amino acid sequences consisting of sequences given in SEQ ID NOS: 12, 13 and 14 respectively.

2. claims: 10(completely); 7, 8, 12-15(partially)

Invention 2 relates to an anti-CD40L (anti-CD252) monoclonal antibody for use in the prevention or treatment of autoimmune disease, more particularly when the anti-CD252 monoclonal antibody comprises the heavy chain CDRs 1-3 amino acid sequences consisting of sequences given in SEQ ID NOS: 19, 20 and 21 respectively and the light-chain CDRs 1-3 amino acid sequences consisting of sequences given in SEQ ID NOS: 26, 27 and 28 respectively.

3. claims: 11(completely); 7, 8, 12-15(partially)

Invention 3 relates to an anti-CD40L (anti-CD252) monoclonal antibody for use in the prevention or treatment of autoimmune disease, more particularly when the anti-CD252 monoclonal antibody comprises the heavy chain CDRs 1-3 amino acid sequences consisting of sequences given in SEQ ID NOS: 33, 34 and 35 respectively and the light-chain CDRs 1-3 amino acid sequences consisting of sequences given in SEQ ID NOS: 40, 41 and 42 respectively.

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 15 82 9426

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

29-11-2017

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
EP 0978287	A1	09-02-2000		CA 2272605 A1 EP 0978287 A1 JP 3914342 B2 JP H11180893 A US 6333035 B1 WO 9915200 A1		01-04-1999 09-02-2000 16-05-2007 06-07-1999 25-12-2001 01-04-1999
WO 2011073180	A1	23-06-2011		EP 2513145 A1 EP 3309176 A1 US 2013018175 A1 US 2015218281 A1 WO 2011073180 A1		24-10-2012 18-04-2018 17-01-2013 06-08-2015 23-06-2011
US 8551477	B1	08-10-2013		US 7291331 B1 US 7531170 B1 US 7807156 B1 US 8101175 B1 US 8551477 B1 US 8956615 B1 US 9873744 B1		06-11-2007 12-05-2009 05-10-2010 24-01-2012 08-10-2013 17-02-2015 23-01-2018
WO 2007133290	A2	22-11-2007		AR 057253 A1 AU 2006343459 A1 BR PI0621065 A2 CA 2633602 A1 CN 101374865 A CR 10069 A EC SP088543 A EP 1973949 A2 JP 2009519718 A KR 20080080639 A MA 30153 B1 TW 200732349 A US 2009053230 A1 US 2010272738 A1 WO 2007133290 A2 ZA 200804868 B		21-11-2007 22-11-2007 29-11-2011 22-11-2007 25-02-2009 10-10-2008 30-07-2008 01-10-2008 21-05-2009 04-09-2008 02-01-2009 01-09-2007 26-02-2009 28-10-2010 22-11-2007 28-10-2009